Skip to main content

Table 3 Changes in laboratory data from baseline, and diuretic use after 1 year of tolvaptan treatment

From: Impact of continued administration of tolvaptan on cirrhotic patients with ascites

(n = 37) Pretreatment Post-treatment p-value
Diuretic
 Furosemide dose (mg/day) 20 (0–80) 20 (0–80) 0.28
 Spironolactone dose (mg/day) 50 (0–150) 37.5 (0–150) 0.50
Laboratory data
 Albumin (g/dL) 2.6 (1.7–4.2) 3.1 (1.5–4.4) < 0.01
 Total bilirubin (mg/dL) 2.0 (0.4–21.7) 1.5 (0.3–8.2) 0.01
 Aspartate aminotransferase (U/L) 42 (13–171) 34 (15–701) 0.09
 Alanine aminotransferase (U/L) 29 (7–144) 20 (9–255) 0.14
 γ-Glutamyl transpeptidase (U/L) 48 (9–229) 40 (12–285) 0.52
 Platelet count (×104/μL) 7.6 (1.5–23.9) 7.7 (1.6–23.6) 0.64
 Hematocrit (%) 28.6 (24.2–37.3) 32.0 (18.8–40.7) 0.06
 Prothrombin time (PT%) 54.5 (19.5–90.3) 60.4 (19.4–89.4) 0.09
 PT/INR 1.32 (0.98–2.84) 1.26 (1.01–2.70) 0.02
 Ammonia (μg/dL) 85 (25–269) 67 (12–212) < 0.01
 α-fetoprotein (ng/mL) 4 (1–210) 3 (1–17,734) 0.79
 Des-gamma-carboxy (mAU/mL) 27 (3–4994) 27 (8–40,510) 0.53
 Blood urea nitrogen (mg/dL) 23.2 (6.0–63.3) 25.4 (6.0–75.2) 0.99
 Creatinine (mg/dL) 1.04 (0.44–3.30) 1.16 (0.50–2.48) 0.09
 eGFR (mL/min/1.73 m2) 49.5 (16.8–107.2) 42.9 (15.3–136.3) 0.42
 Serum sodium (mEq/L) 137 (122–145) 138 (123–144) 0.63
 Modified Child-Pugh (CP) score 11 (8–13) 10 (6–13) < 0.01
 MELD score 12 (2–29) 12 (3–22) 0.13
  1. INR international normalized ratio, eGFR estimated glomerular filtration rate, n number of patients, MELD model for end-stage liver disease. Data are represented as the median (range)